{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:57:57Z","timestamp":1789016277228,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.hoc.2020.06.008","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T08:01:32Z","timestamp":1596614492000},"page":"923-939","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?"],"prefix":"10.1016","volume":"34","author":[{"given":"Rory","family":"McCulloch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2020.06.008_bib1","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"10121","key":"10.1016\/j.hoc.2020.06.008_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.hoc.2020.06.008_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"124","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"10020","key":"10.1016\/j.hoc.2020.06.008_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2020.06.008_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/hon.15_2629","article-title":"Zanubrutinib in patients with relapsed\/refractory mantle cell lymphoma","volume":"37","author":"Song","year":"2019","journal-title":"Hematol Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.hoc.2020.06.008_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hon.55_2630","article-title":"Updated safety and efficacy data in phase 1 trial of patients with mantle cell lymphoma (MCL) treated with Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111)","volume":"37","author":"Tam","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.hoc.2020.06.008_bib7","unstructured":"BeiGene. Brukinsa\u2122 (zanubrutinib) prescribing information. Available at: https:\/\/www.brukinsa.com\/prescribing-information.pdf. Accessed April 3, 2020."},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.008_bib9","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analyisis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.008_bib10","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.hoc.2020.06.008_bib11","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.008_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/hon.2380","article-title":"Predictive factors and outcomes for ibrutinib therapy in relapsed\/refractory mantle cell lymphoma-a \u201creal world\u201d study","volume":"35","author":"Epperla","year":"2017","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.008_bib13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.008_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-019-0209-5","article-title":"Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.008_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.008_bib16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","article-title":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis","volume":"37","author":"Cinar","year":"2013","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.hoc.2020.06.008_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjh.12974","article-title":"Characterization of ibrutinib-sensitive and \u2013resistant mantle lymphoma cells","volume":"166","author":"Ma","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.hoc.2020.06.008_bib19","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"issue":"45","key":"10.1016\/j.hoc.2020.06.008_bib20","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.008_bib21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","article-title":"Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma","volume":"2","author":"Lee","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.008_bib22","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukaemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"36","key":"10.1016\/j.hoc.2020.06.008_bib23","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"issue":"491","key":"10.1016\/j.hoc.2020.06.008_bib24","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.hoc.2020.06.008_bib25","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2020.06.008_bib26","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.008_bib27","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3324\/haematol.2011.040659","article-title":"Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor \u03baB pathways","volume":"97","author":"Medina","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2020.06.008_bib28","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.008_bib29","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1172\/JCI64210","article-title":"A\u00a0microenvironment-mediated c-Myc\/miR-548m\/HDAC6 amplification loop in non-Hodgkin B cell lymphomas","volume":"123","author":"Lwin","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.008_bib30","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.008_bib31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","article-title":"SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in\u00a0vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"29","key":"10.1016\/j.hoc.2020.06.008_bib33","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2020.06.008_bib34","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.008_bib35","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.008_bib36","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumour activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.hoc.2020.06.008_bib37","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.008_bib38","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","article-title":"Egress of CD19(+)CD5(+) cells into the peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients","volume":"122","author":"Chang","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.008_bib39","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.hoc.2020.06.008_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.hoc.2020.06.008_bib41","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.hoc.2020.06.008_bib42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2019-126619","article-title":"Three year update of the phase II ABT-199 (venetoclax) and ibrutinib in mantle cell lymphoma (AIM) study","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.hoc.2020.06.008_bib43","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","article-title":"Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy","volume":"125","author":"de Rooij","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2020.06.008_bib44","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A\u00a0phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2020.06.008_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib46","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","author":"Davids","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.008_bib47","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A\u00a0phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib48","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","article-title":"Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis","volume":"171","author":"Pham","year":"2003","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib49","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-017-0537-5","article-title":"Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed\/progressed after or were refractory\/intolerant to ibrutinib (MCL-004)","volume":"10","author":"Wang","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2020.06.008_bib50","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.hoc.2020.06.008_bib51","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2020.06.008_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.16416","article-title":"Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy","author":"McCulloch","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2020.06.008_bib53","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15107","article-title":"A\u00a0phase II study of carfilzomib in the treatment of relapsed\/refractory mantle cell lymphoma","volume":"184","author":"Lee","year":"2019","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1016\/j.hoc.2020.06.008_bib54","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.hoc.2020.06.008_bib55","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2019-127509","article-title":"Results from a first-in-human, proof-of-concept phase 1 trial in pretreated b-cell malignancies for LOXO-305, a next-generation, highly selective, non-covalent BTK inhibitor","volume":"134","author":"Mato","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2020.06.008_bib56","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/annonc\/mds054","article-title":"Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed\/refractory mantle cell lymphoma: a multicenter experience","volume":"23","author":"Le Gouill","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2020.06.008_bib57","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41409-018-0207-4","article-title":"Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT chronic malignancies and lymphoma working parties","volume":"54","author":"Dreger","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl. 1","key":"10.1016\/j.hoc.2020.06.008_bib58","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/blood-2019-125947","article-title":"Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 169 patients","volume":"134","author":"McCulloch","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.hoc.2020.06.008_bib59","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood-2019-126064","article-title":"KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T\u00a0cell therapy, in patients (Pts) With Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030071X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985882030071X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:14:38Z","timestamp":1760184878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985882030071X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S088985882030071X"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.008","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2020.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}